Clinical studies showed that mutations on TP53 reduce responsiveness to first-line tyrosine kinase inhibitors in EGFR-mutated non–small cell lung cancer (NSCLC) patients [42]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.